MRK
Merck & Co., Inc.Price & Indicators
Blended from price, positioning & fundamentals · daily-close · not investment advice.
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - General — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MRK
this stock
Merck & Co., Inc.
|
$319.99B | +24.0% | +1.4% | 36.5 | 1.2% |
|
LLY
ELI LILLY & Co
|
$1.14T | +13.1% | +44.7% | 43.1 | 1.0% |
|
JNJ
Johnson & Johnson
|
$633.19B | +27.8% | +6.0% | 30.5 | 1.1% |
|
ABBV
AbbVie Inc.
|
$461.26B | +15.2% | +8.6% | 128.6 | 1.3% |
|
NVS
Novartis AG
|
$305.10B | +19.5% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MRK | +3.3% | +13.0% | +17.6% | +0.8% | +24.0% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +1.9% | +14.2% | +9.6% | +1.1% | +14.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.